5AAC
Structure of C1156Y Mutant Human Anaplastic Lymphoma Kinase in Complex with Crizotinib
Summary for 5AAC
Entry DOI | 10.2210/pdb5aac/pdb |
Related | 5A9U 5AA8 5AA9 5AAA 5AAB |
Descriptor | ALK TYROSINE KINASE RECEPTOR, 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-amine (3 entities in total) |
Functional Keywords | transferase, receptor tyrosine kinase, anaplastic lymphoma kinase, inhibitor, mutant |
Biological source | HOMO SAPIENS (HUMAN) |
Total number of polymer chains | 1 |
Total formula weight | 37419.72 |
Authors | McTigue, M.,Deng, Y.,Liu, W.,Brooun, A.,Stewart, A. (deposition date: 2015-07-23, release date: 2016-06-08, Last modification date: 2024-01-10) |
Primary citation | Shaw, A.T.,Friboulet, L.,Leshchiner, I.,Gainor, J.F.,Bergqvist, S.,Brooun, A.,Burke, B.J.,Deng, Y.,Liu, W.,Dardaei, L.,Frias, R.L.,Schultz, K.R.,Logan, J.,James, L.P.,Smeal, T.,Timofeevski, S.,Katayama, R.,Iafrate, A.J.,Le, L.,Mctigue, M.,Getz, G.,Johnson, T.W.,Engelman, J.A. Resensitization to Crizotinib by the Lorlatinib Alk Resistance Mutation L1198F. N.Engl.J.Med., 374:54-, 2016 Cited by PubMed: 26698910DOI: 10.1056/NEJMOA1508887 PDB entries with the same primary citation |
Experimental method | X-RAY DIFFRACTION (1.7 Å) |
Structure validation
Download full validation report